The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
Blood Cancer Journal, Published online: 18 August 2023; doi:10.1038/s41408-023-00896-6The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 18, 2023 Category: Hematology Authors: Marthe Minderman Hildo Lantermans Carmen van der Zwaan Arie J. Hoogendijk Maartje van den Biggelaar Marie Jos é Kersten Marcel Spaargaren Steven T. Pals Source Type: research
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Blood Cancer Journal, Published online: 18 August 2023; doi:10.1038/s41408-023-00889-5Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 18, 2023 Category: Hematology Authors: Sohee Park Ju Hwan Kim Songhee Kim Jisu Kang Seoyoung Moon Seok Jin Kim Ju-Young Shin Source Type: research
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
Blood Cancer Journal, Published online: 18 August 2023; doi:10.1038/s41408-023-00900-zLong-term outcomes of allogeneic stem cell transplant in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 18, 2023 Category: Hematology Authors: Walker M. Schmidt Nirosha D. Perera Francis K. Buadi Suzanne R. Hayman Shaji K. Kumar Angela Dispenzieri David Dingli Joselle Cook Martha Q. Lacy Prashant Kapoor Nelson Leung Eli Muchtar Rahma M. Warsame Taxiarchis Kourelis Moritz Binder Wilson I. Gonsalv Source Type: research
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
Blood Cancer Journal, Published online: 18 August 2023; doi:10.1038/s41408-023-00895-7Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 18, 2023 Category: Hematology Authors: William G. Breen Jason R. Young Matthew A. Hathcock Roman O. Kowalchuk Matthew P. Thorpe Radhika Bansal Arushi Khurana N. Nora Bennani Jonas Paludo Jose Villasboas Bisneto Yucai Wang Stephen M. Ansell Jennifer L. Peterson Patrick B. Johnston Scott C. Lest Source Type: research
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
Blood Cancer Journal, Published online: 11 August 2023; doi:10.1038/s41408-023-00891-xReal-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 11, 2023 Category: Hematology Authors: Maymona G. Abdelmagid Aref Al-Kali Mark R. Litzow Kebede H. Begna William J. Hogan Mirinal S. Patnaik Shahrukh K. Hashmi Michelle A. Elliott Hassan Alkhateeb Omer S. Karrar Farah Fleti Mohammed H. Elnayir Candido E. Rivera Hemant S. Murthy James M. Foran Source Type: research
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Blood Cancer Journal, Published online: 09 August 2023; doi:10.1038/s41408-023-00886-8Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 9, 2023 Category: Hematology Authors: Christopher J. Ferreri Michelle A. T. Hildebrandt Hamza Hashmi Leyla O. Shune Joseph P. McGuirk Douglas W. Sborov Charlotte B. Wagner M. Hakan Kocoglu Aaron Rapoport Shebli Atrash Peter M. Voorhees Jack Khouri Danai Dima Aimaz Afrough Gurbakhash Kaur Larr Source Type: research
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
Blood Cancer Journal, Published online: 09 August 2023; doi:10.1038/s41408-023-00894-8Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 9, 2023 Category: Hematology Authors: Wan-Hsuan Lee Ming-Tao Tsai Cheng-Hong Tsai Feng-Ming Tien Min-Yen Lo Mei-Hsuan Tseng Yuan-Yeh Kuo Ming-Chih Liu Yi-Tsung Yang Jui-Che Chen Jih-Luh Tang Hsun-I Sun Yi-Kuang Chuang Liang-In Lin Wen-Chien Chou Chien-Chin Lin Hsin-An Hou Hwei-Fang Tien Source Type: research
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis
Blood Cancer Journal, Published online: 09 August 2023; doi:10.1038/s41408-023-00893-9Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 9, 2023 Category: Hematology Authors: Tomohiko Yamada Nobuhiro Hiramoto Takuto Mori Daisuke Yamashita Yukimasa Tai Ryusuke Yamamoto Masashi Nishikubo Hayato Maruoka Kana Sakamoto Kengo Takeuchi Yasuhito Nannya Seishi Ogawa Takayuki Ishikawa Source Type: research
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Blood Cancer Journal, Published online: 09 August 2023; doi:10.1038/s41408-023-00890-yIbrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 9, 2023 Category: Hematology Authors: Yi Miao Yeqin Sha Yi Xia Shuchao Qin Rui Jiang Luomengjia Dai Hui Shen Tonglu Qiu Wei Wu Jingyan Qiu Yilian Yang Chongyang Ding Yujie Wu Lei Fan Wei Xu Jianyong Li Huayuan Zhu Source Type: research
Multiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells
Blood Cancer Journal, Published online: 09 August 2023; doi:10.1038/s41408-023-00892-wMultiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 9, 2023 Category: Hematology Authors: Sylvain Mayeur Anne Molitor Laurent Miguet Lucie Rigolot Lydie Naegely Tristan Stemmelen S ébastien Meyer Elise Toussaint Laurent Vallat Alice Eischen Marie-Pierre Chenard Manuela Tavian Seiamak Bahram Raphael Carapito Alina Nicolae Source Type: research
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood Cancer Journal, Published online: 01 August 2023; doi:10.1038/s41408-023-00879-7Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 1, 2023 Category: Hematology Authors: Noopur Raje Kenneth Anderson Hermann Einsele Yvonne Efebera Francesca Gay Sarah P. Hammond Alexander M. Lesokhin Sagar Lonial Heinz Ludwig Philippe Moreau Krina Patel Karthik Ramasamy Maria-Victoria Mateos Source Type: research
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
Blood Cancer Journal, Published online: 28 July 2023; doi:10.1038/s41408-023-00887-7Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 28, 2023 Category: Hematology Authors: Alessandra Carobbio Alessandro Maria Vannucchi Elisa Rumi Valerio De Stefano Alessandro Rambaldi Giuseppe Carli Maria Luigia Randi Heinz Gisslinger Francesco Passamonti Juergen Thiele Naseema Gangat Ayalew Tefferi Tiziano Barbui Source Type: research
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms
Blood Cancer Journal, Published online: 26 July 2023; doi:10.1038/s41408-023-00884-wIn-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 26, 2023 Category: Hematology Authors: Emily Ayers Glenda Canderan Michael E. Williams Behnam Keshavarz Craig A. Portell Jeffrey M. Wilson Judith A. Woodfolk Source Type: research
Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA
Blood Cancer Journal, Published online: 26 July 2023; doi:10.1038/s41408-023-00885-9Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 26, 2023 Category: Hematology Authors: Royston Ponraj Adam Bryant Lindsay Dunlop Heather Range Cherry Cobrador Silvia Ling Danny Hsu Source Type: research
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Blood Cancer Journal, Published online: 25 July 2023; doi:10.1038/s41408-023-00882-yBortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 25, 2023 Category: Hematology Authors: Carlyn Rose Tan Andriy Derkach David Nemirovsky Amanda Ciardiello Benjamin Diamond Malin Hultcrantz Hani Hassoun Sham Mailankody Urvi Shah Kylee Maclachlan Dhwani Patel Oscar B. Lahoud Heather J. Landau David J. Chung Gunjan L. Shah Michael Scordo Sergio Source Type: research
